QbD: Regulatory and Scientific Possibilities and Challenges
Gert Ragnarsson, Director of the Swedish Medical Projects Agency, discusses the biggest milestones in QbD over the last decade, including:
- The establishment of harmonised guidelines
- The Formation of the EMA
- The recent document published by the FDA, which is a significant step in dealing with advanced formulations
He also looks to the future growth of generics and the effects QbD and PAT will have on that market.
Please note: That all fields marked with an asterisk (*) are required.
Where did you hear about us?